What is the 13F Pro Quality Score for LFMD?

13F Pro ranks LifeMD, Inc. (LFMD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View LFMD's current score at https://13fpro.ai/research/LFMD (free sign-up required for the full ranking).

Which hedge funds own the most LFMD stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of LFMD include BlackRock,, VANGUARD CAPITAL MANAGEMENT, ROYCE & ASSOCIATES. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/LFMD as soon as new 13F filings post.

Where does 13F Pro source LFMD data?

All LifeMD, Inc. fundamentals and ownership data come directly from SEC EDGAR. LifeMD, Inc. files with the SEC under CIK 948320. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is LFMD in?

LifeMD, Inc. (LFMD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is LFMD research updated on 13F Pro?

LFMD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

LifeMD, Inc.(LFMD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 948320 LFMD stock profile & AI dashboard →

13F Pro Quality Score

40.0/100

Rank #1,955 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

84.6/100

Profitability

33.5/100

Balance Sheet

11.3/100

Earnings Quality

30.0/100

Free Cash Flow

45.9/100

Institutional Flow

23.3/100

Revenue Scale

26.1/100

Dilution Risk

24.6/100

LFMD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for LifeMD, Inc. (LFMD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LFMD at 40.0/100 on a 32-signal composite quality model, placing it at rank #1,955 of 2,879 stocks — the bottom half of the AI-ranked universe. LFMD scores in the top quartile across revenue growth (84.6). Areas of concern include balance sheet strength (11.3) and institutional flow (23.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 24.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), LifeMD, Inc. reports quarterly revenue of $50.2M, net income of $-8.9M, free cash flow of $339.4K. Top institutional holders of LFMD by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, ROYCE & ASSOCIATES, based on the most recent SEC filings. LFMD trades on the Nasdaq exchange and files with the SEC under CIK 948320. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LFMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LifeMD, Inc. directly from SEC EDGAR. LifeMD, Inc.'s 13F Pro composite quality score has ranged between 27 and 47 since 2021, currently 40.0 — an improving long-term trajectory across 27 quarterly and live scoring snapshots.

✦

Fun facts about LifeMD, Inc.

Quirks, history, and lore behind LFMD — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · small-cap · listed on Nasdaq · headquartered in New York.
2
The Numbers
Annual revenue in the low hundreds of millions of dollars, with a business model built on recurring subscription revenue from patients rather than one-time visits.
3
The History
Founded in the late 2010s, it rode the wave of telehealth adoption — and got a serious tailwind from the pandemic forcing everyone to see doctors on a screen.
4
The Secret
It's essentially a direct-to-consumer pharmacy and clinic hybrid, cutting out the middleman so patients get prescriptions without ever sitting in a waiting room.
5
The Lore
The company expanded hard into men's health — think hair loss and other sensitive topics guys won't Google at work — making awkward conversations mercifully digital.
6
The Giveaway
Its flagship brand Shapiro MD targets hair loss, and its WorkSimpli subsidiary sells PDF software — making it possibly the only telehealth company that also wants to manage your documents.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$50.2M

Net Income

Q1 2026

$-8.9M

Free Cash Flow

Q1 2026

$339.4K

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+63.0% YoY

$194.1MFY 2025

FY20 $37.3MFY21 $92.9MFY22 $119.0MFY25 $194.1M

Net Income

+131.5% YoY

$14.4MFY 2025

FY20 $-58.6MFY21 $-60.9MFY22 $-45.5MFY25 $14.4M

Operating Income

+82.3% YoY

$-7.7MFY 2025

FY20 $-57.8MFY21 $-54.3MFY22 $-43.4MFY25 $-7.7M

EPS (Diluted)

$0.25FY 2025

FY20 —FY21 —FY22 —FY25 $0.25

Total Assets

+174.3% YoY

$70.4MFY 2025

FY20 $13.1MFY21 $49.9MFY22 $25.7MFY25 $70.4M

Op. Cash Flow

+136.1% YoY

$8.3MFY 2025

FY20 $-12.1MFY21 $-33.1MFY22 $-22.9MFY25 $8.3M

Metric	FY 2025	FY 2022	FY 2021	FY 2020	FY 2017	FY 2016
Revenue	$194.1M +63.0%	$119.0M +28.2%	$92.9M +149.0%	$37.3M +912.9%	$3.7M -29.7%	$5.2M
Net Income	$14.4M +131.5%	$-45.5M +25.2%	$-60.9M -3.8%	$-58.6M -4763.1%	$-1.2M -8.9%	$-1.1M
Operating Income	$-7.7M +82.3%	$-43.4M +20.0%	$-54.3M +6.1%	$-57.8M -4607.1%	$-1.2M -4.6%	$-1.2M
EPS (Diluted)	$0.25	—	—	—	$-0.03 +0.0%	$-0.03
Total Assets	$70.4M +174.3%	$25.7M -48.6%	$49.9M +282.4%	$13.1M +932.9%	$1.3M +60.0%	$789.8K
Operating Cash Flow	$8.3M +136.1%	$-22.9M +30.7%	$-33.1M -172.7%	$-12.1M -1384.5%	$-817.2K -100.3%	$-407.9K

AI Insight: LFMD Financial Trends

LifeMD shows extreme quarterly revenue volatility, swinging from $64M in Q2 2025 to $7M in Q4 2025, with inconsistent profitability throughout.

• Revenue fluctuated wildly from $64M in Q2 2025 to $7M in Q4 2025, then rebounded to $50M in Q1 2026.

• Operating income turned positive at $3M in Q1 2025 but deteriorated to -$9M by Q1 2026.

• Equity improved from negative $8M in Q3 2024 to positive $23M in Q4 2025.

⚠ Q4 quarters show dramatic revenue drops to $5M and $7M, suggesting potential seasonal or operational disruptions.

⚠ Operating cash flow turned negative in Q3 2025 and remained weak at $0M in Q1 2026.

AI Insight: LFMD Ratio Trends

LifeMD shows extreme quarterly volatility with operating margins swinging from +4.0% in Q1 2025 to -87.9% in Q4 2025.

• Operating margin deteriorated from 4.0% in Q1 2025 to -17.8% in Q1 2026.

• Net profit margin turned negative at -17.7% in Q1 2026 versus 2.2% in Q1 2025.

• Return on assets collapsed from 7.5% in Q1 2025 to -50.6% in Q1 2026.

⚠ Q4 2025 showed massive -87.9% operating margin decline, signaling potential operational disruption.

⚠ TTM figures show positive 2.3% net margin despite recent quarterly losses, indicating mixed performance.

Get alerted when LFMD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for LifeMD, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of LFMD

BlackRock, Inc.
$10.1M2,809,025 sh
VANGUARD CAPITAL MANAGEMENT LLC
$6.0M1,663,696 sh
ROYCE & ASSOCIATES LP
$4.3M1,201,651 sh
RENAISSANCE TECHNOLOGIES LLC
$4.0M1,118,325 sh
STATE STREET CORP
$3.9M1,075,408 sh
GEODE CAPITAL MANAGEMENT, LLC
$3.7M1,019,441 sh
FEDERATED HERMES, INC.
$3.7M1,019,077 sh
PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.
$3.2M895,424 sh
BRC Group Holdings, Inc.
$3.1M871,580 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$1.7M465,193 sh

Fund	Value	Shares
BlackRock, Inc.	$10.1M	2,809,025
VANGUARD CAPITAL MANAGEMENT LLC	$6.0M	1,663,696
ROYCE & ASSOCIATES LP	$4.3M	1,201,651
RENAISSANCE TECHNOLOGIES LLC	$4.0M	1,118,325
STATE STREET CORP	$3.9M	1,075,408
GEODE CAPITAL MANAGEMENT, LLC	$3.7M	1,019,441
FEDERATED HERMES, INC.	$3.7M	1,019,077
PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.	$3.2M	895,424
BRC Group Holdings, Inc.	$3.1M	871,580
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$1.7M	465,193

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put LFMD on your watchlist

Track score changes the day LifeMD, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is LFMD a good stock to buy?

13F Pro's AI-powered analysis of LifeMD, Inc. (LFMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LFMD are available on the LFMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own LFMD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LFMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of LifeMD, Inc.'s investment landscape.